- Acquired by Epirus Biopharmaceuticals, Dec 2009
- Raised $1M funding round, Mar 2012
About
NeuroMed Pharmaceuticals is offering Yac-101, a potential treatment for injuries involving neuro-degeneration. Yac-101 is based on specific and differentiating metal chelation that may prevent various types of reactive oxygen species generated directly or via metal mediation. The product also has the potential to maintain cytosolic calcium homeostasis, keep mitochondrial function following ion-loading insults, prevent cell membrane damage induced by lipid peroxidation, and preserve energy stores. NeuroMed Pharmaceuticals is now integrated within its Canadian purchaser, Zalicus Pharmaceuticals, which was in turn was acquired by Epirus Biopharmaceuticals in July 2014, both companies located in New England, USA. The later picture: The U.S. arm of Israel-based Taro Pharmaceuticals bought Zalicus for $3.8 million in cash and a $3.8 million limited recourse note that matures in 2017. Sun controls Taro after a series of complex negotiations that began in 2007 and reached a conclusion in 2013. Zalicus, a subsidiary of Boston-based Epirus Biopharmaceuticals, develops biosimilar drugs, is developing a pain management drug candidate called Z944.
Funding history · 1 round · $1.0M total
Q&A
- What is NeuroMed's primary focus?
- NeuroMed Pharmaceuticals focuses on developing treatments for neurological degenerative diseases, specifically offering Yac-101, a potential treatment for neuro-degeneration injuries.
- When was NeuroMed founded?
- NeuroMed was founded in January 2005.
- What is the current status of NeuroMed?
- NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009 and is currently inactive.
- What was the total amount raised by NeuroMed?
- NeuroMed raised a total of $1,000,000.
- When was NeuroMed's last funding round?
- NeuroMed's last funding round occurred in March 2012, raising $1,000,000.
- What is the core technology behind NeuroMed's product Yac-101?
- Yac-101 is based on specific and differentiating metal chelation, designed to prevent reactive oxygen species and maintain cellular functions like cytosolic calcium homeostasis and mitochondrial function.
- Who acquired NeuroMed?
- NeuroMed was acquired by Epirus Biopharmaceuticals in December 2009.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/8666871 |
Identifiers & details
| Former names | CombinatorX, NeuroMed |
|---|---|
| Founded | 2005-1 |
| Status reason | Acquired (Inactive) by Epirus Biopharmaceuticals on Dec 2009 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Epirus Biopharmaceuticals 2009-12
Radar intelligence
Patents
| EPO | 60 |
|---|
Publications (Crossref)
| Works | 10 |
|---|